ZY19489

Zydus Cadila

Product vision
  • Uncomplicated malaria treatment for single-exposure radical cure (SERC) and/or resistance management
MoA
  • Unknown 

Key features
  • Predicted human dose 900mg for a 9-log parasite killing
  • Low resistance potential from in vitro studies
Challenges
  • Synthesis and cost of goods

Status
  • First-in-Human study started in February 2019

Next milestone
  • Initiate multiple ascending dose (MAD) phase I study and phase I combination study
Previously
  • Discovery partnership between MMV and AstraZeneca, Bangalore
  • Name AZ13721412; full reference name is MMV674253
MMV Project Director
  • Illaria Di Resta